Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.

Launching: Thursday 12th December 2024
ADVANCED SEARCH
Log in
Top
Annals of Hematology

Open Access 04-11-2024 | Lymphoma | Case Report

A rare case of splenic marginal zone lymphoma with MYD88 mutation transformed into diffuse large B-cell lymphoma: case report and literature review

Authors: Yuzhan Chen, Ting Chen, Shufang Fan, Qitian Mu, Guifang Ouyang

Published in: Annals of Hematology

Login to get access

Abstract

In indolent lymphomas, histological transformation (HT) often results in a poor prognosis and presents a significant challenge in the management of these lymphomas. Previous studies have indicated that MYD88 mutations are associated with transformation in certain haematologic malignancies. We report a rare case of splenic marginal zone lymphoma (SMZL) harbouring an MYD88 mutation, which was transformed into diffuse large B-cell lymphoma (DLBCL) and accompanied by newly emerging genetic abnormalities. The role of the MYD88 gene in SMZL is currently unclear. Through this case, we reviewed relevant studies, which indicated that MYD88 mutations, along with other genetic anomalies, may play a significant role in this process. In the future, it is essential to collect more of these rare cases for further research.
Literature
1.
Deaglio S, Vaisitti T (2022) A new taxonomy for splenic marginal zone lymphoma. Blood 139(5):644–645CrossRefPubMed
2.
Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, de O, Berti E et al (2022) The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia 36(7):1720–1748CrossRefPubMedPubMedCentral
3.
Bastidas-Mora G, Beà S, Navarro A, Gine E, Costa D, Delgado J et al (2022) Clinico-biological features and outcome of patients with splenic marginal zone lymphoma with histological transformation. Br J Haematol 196(1):146–155CrossRefPubMed
4.
Camacho FI, Mollejo M, Mateo M-S, Algara P, Navas C, Hernández J-M et al (2001) Progression to Large B-Cell Lymphoma in Splenic Marginal Zone Lymphoma: A Description of a Series of 12 Cases. Am J Surg Pathol 25(10):1268–1276CrossRefPubMed
5.
Dungarwalla M, Appiah-Cubi S, Kulkarni S, Saso R, Wotherspoon A, Osuji N et al (2008) High-grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis. Br J Haematol 143(1):71–74CrossRefPubMed
6.
Alderuccio JP, Zhao W, Desai A, Gallastegui N, Ramdial J, Kimble E et al (2018) Risk Factors for Transformation to Higher-Grade Lymphoma and Its Impact on Survival in a Large Cohort of Patients With Marginal Zone Lymphoma From a Single Institution. JCO 36(34):3370–3380CrossRef
7.
Conconi A, Franceschetti S, Aprile Von Hohenstaufen K, Margiotta-Casaluci G, Stathis A, Moccia AA et al (2015) Histologic transformation in marginal zone lymphomas. Ann Oncol 26(11):2329–2335CrossRefPubMed
8.
Meyer AH, Stroux A, Lerch K, Eucker J, Eitle J, Hohloch K et al (2014) Transformation and additional malignancies are leading risk factors for an adverse course of disease in marginal zone lymphoma. Ann Oncol 25(1):210–215CrossRefPubMed
9.
Bonfiglio F, Bruscaggin A, Guidetti F, di Bergamo LT, Faderl M, Spina V et al Genetic and phenotypic attributes of splenic marginal zone lymphoma
10.
Alonso-Álvarez S, Magnano L, Alcoceba M, Andrade-Campos M, Espinosa-Lara N, Rodríguez G et al (2017) Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group. Br J Haematol 178(5):699–708CrossRefPubMed
11.
Rossi D, Cerri M, Capello D, Deambrogi C, Rossi FM, Zucchetto A et al (2008) Biological and clinical risk factors of chronic lymphocytic leukaemia transformation to Richter syndrome. Br J Haematol 142(2):202–215CrossRefPubMed
12.
Lenglet J, Traullé C, Mounier N, Benet C, Munoz-Bongrand N, Amorin S et al (2014) Long-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment. Leuk Lymphoma 55(8):1854–1860CrossRefPubMed
13.
Kalashnikov I, Tanskanen T, Viisanen L, Malila N, Jyrkkiö S, Leppä S (2023) Transformation and survival in marginal zone lymphoma: a Finnish nationwide population-based study. Blood Cancer J 13(1):62CrossRefPubMedPubMedCentral
14.
Kalashnikov I, Tanskanen T, Pitkäniemi J, Malila N, Jyrkkiö S, Leppä S (2021) Transformation and outcome of nodular lymphocyte predominant Hodgkin lymphoma: a Finnish Nationwide population-based study. Blood Cancer J 11(12):203CrossRefPubMedPubMedCentral
15.
Casulo C, Burack WR, Friedberg JW (2015) Transformed follicular non-Hodgkin lymphoma. Blood 125(1):40–47CrossRefPubMed
16.
Sander C, Yano T, Clark H, Harris C, Longo D, Jaffe E et al (1993) p53 mutation is associated with progression in follicular lymphomas. Blood 82(7):1994–2004CrossRefPubMed
17.
Pinyol M, Cobo F, Bea S, Jares P, Nayach I, Fernandez PL et al (1998) p16INK4a Gene Inactivation by Deletions, Mutations, and Hypermethylation Is Associated With Transformed and Aggressive Variants of Non-Hodgkin’s Lymphomas. Blood 91(8):2977–2984CrossRefPubMed
18.
Szereday Z, Csernus B, Nagy M, László T, Warnke RA, Matolcsy A (2000) Somatic Mutation of the 5′ Noncoding Region of the BCL-6 Gene Is Associated with Intraclonal Diversity and Clonal Selection in Histological Transformation of Follicular Lymphoma. Am J Pathol 156(3):1017–1024CrossRefPubMedPubMedCentral
19.
Okosun J, Bödör C, Wang J, Araf S, Yang C-Y, Pan C et al (2014) Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat Genet 46(2):176–181CrossRefPubMed
20.
Zanwar S, Abeykoon JP, Durot E, King R, Perez Burbano GE, Kumar S et al (2020) Impact of MYD88 L265P mutation status on histological transformation of Waldenström Macroglobulinemia. Am J Hematol 95(3):274–281CrossRefPubMed
21.
Kosako H, Yamashita Y, Tanaka K, Mishima H, Iwamoto R, Kinoshita A et al (2022) Intestinal Mucosa-Associated Lymphoid Tissue Lymphoma Transforming into Diffuse Large B-Cell Lymphoma in a Young Adult Patient with Neurofibromatosis Type 1: A Case Report. Med (Kaunas) 58(12):1830
22.
Kusaba Y, Takeda Y, Abe S, Tsukada A, Naka G (2022) T790M mutation positive squamous cell carcinoma transformation from EGFR-mutated lung adenocarcinoma after low dose erlotinib: A case report and literature review. Med (Baltim) 101(32):e29682CrossRef
23.
Zeng J, Ding X, Ding J, Wang X (2023) Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy. Front Immunol 14:1275957CrossRefPubMedPubMedCentral
24.
Nelson BE, Reddy NK, Huse JT, Amini B, Nardo M, Gouda M et al (2023) Histological transformation to gliosarcoma with combined BRAF/MEK inhibition in BRAF V600E mutated glioblastoma. NPJ Precis Oncol 7:47CrossRefPubMedPubMedCentral
25.
Lim S, Koh J, Bae JM, Yun H, Lee C, Paik JH et al (2024) Transformation of t(14;18)-negative follicular lymphoma to plasmablastic lymphoma: a case report with analysis of genetic evolution. Diagn Pathol 19:86CrossRefPubMedPubMedCentral
26.
Parry M, Rose-Zerilli MJ, Ljungström V, Gibson J, Wang J, Walewska R et al (2015) Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing. Clin Cancer Res 21(18):4174–4183CrossRefPubMedPubMedCentral
27.
Phelan JD, Young RM, Webster DE, Roulland S, Wright GW, Kasbekar M et al (2018) A Multiprotein Supercomplex Controlling Oncogenic Signaling in Lymphoma. Nature 560(7718):387–391CrossRefPubMedPubMedCentral
28.
29.
Vegivinti CTR, Keesari PR, Veeraballi S, Martins Maia CMP, Mehta AK, Lavu RR et al (2023) Role of innate immunological/inflammatory pathways in myelodysplastic syndromes and AML: a narrative review. Exp Hematol Oncol 12:60CrossRefPubMedPubMedCentral
30.
Treon SP, Xu L, Guerrera ML, Jimenez C, Hunter ZR, Liu X et al (2020) Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies. J Clin Oncol 38(11):1198–1208CrossRefPubMedPubMedCentral
31.
Rodriguez S, Celay J, Goicoechea I, Jimenez C, Botta C, Garcia-Barchino M-J et al (2022) Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma. Sci Adv. 8(3):eabl4644
32.
Cataisson C, Salcedo R, Hakim S, Moffitt BA, Wright L, Yi M et al (2012) IL-1R–MyD88 signaling in keratinocyte transformation and carcinogenesis. J Exp Med 209(9):1689–1702CrossRefPubMedPubMedCentral
33.
Gruffaz M, Vasan K, Tan B, Ramos Da Silva S, Gao S-J (2017) TLR4-Mediated Inflammation Promotes KSHV-Induced Cellular Transformation and Tumorigenesis by Activating the STAT3 Pathway. Cancer Res 77(24):7094–7108CrossRefPubMedPubMedCentral
Metadata
Title
A rare case of splenic marginal zone lymphoma with MYD88 mutation transformed into diffuse large B-cell lymphoma: case report and literature review
Authors
Yuzhan Chen
Ting Chen
Shufang Fan
Qitian Mu
Guifang Ouyang
Publication date
04-11-2024
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-024-06080-5
SPONSORED

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

In this webinar, Professor Martin Dreyling and an esteemed international panel of CAR T-cell therapy experts discuss the latest data on the safety, efficacy, and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL.

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by:
  • Novartis Pharma AG
Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare
Watch now
Image Credits